期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

罗格列酮对兔血脂紊乱及动脉脂质沉着的影响 被引量：3

下载PDF
导出
摘要 目的探讨过氧化物酶体增殖物活化型受体γ(PPARγ)激动剂罗格列酮对兔血脂紊乱及动脉脂质沉着的作用。方法大耳白兔37只随机分为3组。空白组、模型组、干预组。实验第14周末取血测定血脂谱,取主动脉进行苏丹红脂肪染色观察动脉脂质沉着情况,计算斑块面积占主动脉内膜总面积的百分比。结果模型组TC、TG、LDL-C、HDL-C与空白组比较显著升高,苏丹红染色显示动脉内壁脂质沉着面积(74.68±11.89)%。干预组经罗格列酮治疗后较模型组TC、TG、LDL-C水平均有不同程度的降低,HDL-C水平显著升高,主动脉斑块面积(29.93±11.54)%(P<0.001)。结论罗格列酮可调节兔血脂紊乱,并对动脉粥样硬化有一定的抑制作用。
作者 王萍萍 邵明柏 李杰 王新莉 常亚东
机构地区 吉林大学第一医院干部病房 天津代谢病医院 长春市公安局交通警察支队法医室
出处 《中国老年学杂志》 CAS CSCD 北大核心 2007年第6期537-539,共3页 Chinese Journal of Gerontology
基金 吉林省发改委科研基金资助(2005)
关键词 过氧化物酶体增殖物活化型受体-γ 罗格列酮 动脉粥样硬化 兔
分类号 R589.2 [医药卫生—内分泌] R543.1 [医药卫生—心血管疾病]
  • 相关文献

参考文献8

  • 1Celi FS,Shuldiner AR.The role of peroxisome proliferator-activated gamma in diabetes and obesity[J].Curr Diab Rep,2002 ;2(2):179-85.
  • 2Deeb SS,Fajas L,Nemoto M,et al.A Prol 2 Ala substitution in PPAR-2 associated with decreased receptor activity,lower body mass index and improved insulin sensitivity[J].Nat Genet,1998 ;20(3):284-7.
  • 3王朝晖,罗丰,刘小楣.PPARγ激活剂罗格列酮对兔动脉粥样硬化斑块消退的影响[J].药学学报,2005,40(11):1051-1053. 被引量：6
  • 4颜彦,王翔飞,张庆勇,崔杰峰,王颉,朱文青,王齐兵,钱菊英,葛均波.罗格列酮对兔动脉粥样硬化的预防作用[J].复旦学报（医学版）,2005,32(5):601-603. 被引量：7
  • 5Mohanty P,Aljada A,Ghanim H,et al.Rosiglitazone improves vascular reactivity,inhibits reactive oxygen species (ROS) generation,reduces subunit expression in mononuclear cells(MNC) and reduces C reactive protein (CRP) and monocyte chemotactic protein 21 (MCP21):evidence of a potent inflammatory effect[J].Diabetes,2001 ;50 (s2):A68.
  • 6Marx N,Mach F,Sauty A,et al.Peroxisome prolfferator activated receptorγ activators inhibit IFN2γ-induced expression of the T cell active CXC chemokines IP-10,Mig,and I-TAC in human endothelial cells[J].J Immunol,2000; 164(12):6503-8.
  • 7McGarry JD.Banting lecture 2001:dysregulation of fatty acid metabolism in the etiology of type 2 diabetes.Diabetes,2002 ;51 (1):7-18.
  • 8Walker AB,Chattington PD,Buckingham RE,et al.The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats[J].Diabetes,1999;48(7):1448-53.

二级参考文献21

  • 1ZhangJT.现代药理学实验方法 [M].Beijing: Beijing Medical University and Peking Union Medical College United Press,1998..
  • 2Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res,2001,88 (2) :E14.
  • 3Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes ,2002,51 (9) :2796.
  • 4Ricote M, Huang J, Fajas L, et al. Expression of peroxisome proliferators-activated receptor-γ (PPAR-γ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA, 1998,95 (13): 7614.
  • 5Hsueh WA, Jackson S, Law RE. Control of vascular cell proliferation and migration by PPAR-γ: a new approach to the macrovascular complications of diabetes. Diabetes Care ,2001,24(2) :392.
  • 6Diep QN, El Mabrouk M, Cohn JS, et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin Ⅱ-infused rats: role of peroxisome proliferator-activated receptors-gamma. Circulation, 2002,105 ( 19 ): 2296.
  • 7Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med,1999,340(2): 115.
  • 8Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res ,2001,88(2) :E14.
  • 9Pasceri V, Wu HD, Willerson JT, et al. Modulation of vascular inflammation in vitro and vivo by peroxisome proliferator-activated receptors-γ activators. Circulation ,2000,101 (3) :235.
  • 10Ricote M, Li A, Willson TM, et al. The peroxisome proliferatorsactivated receptor-γ is a negative regulator of macrophage activation. Nature, 1998; 391 (6662): 79.

共引文献11

同被引文献42

引证文献3

二级引证文献5

中国老年学杂志
2007年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部